NCT05270460View on ClinicalTrials.gov

Safety, PK and Efficacy of PCS12852 on Gastric Emptying Rate in Patients With Moderate to Severe Gastroparesis

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

March 9, 2022

Primary Completion Date

September 29, 2022

Study Completion Date

October 6, 2022

Conditions
Gastroparesis
Interventions
DRUG

PCS12852

PCS12852 oral tablet administered once daily

DRUG

Placebo

Placebo comparator oral tablet administered once daily

Trial Locations (9)

11023

Long Island Gastrointestinal Research Group, Great Neck

27612

M3 Wake Research, Raleigh

33135

APF Research, LLC, Miami

33183

International Research Associates, LLC, Miami

40202

University of Louisville, Louisville

71220

Delta Research Partners, Bastrop

79905

Texas Tech University, El Paso

90717

Torrance Clinical Research Institute, Inc., Lomita

92108

TriWest Research Associates, San Diego

Sponsors
All Listed Sponsors
lead

Processa Pharmaceuticals

INDUSTRY

NCT05270460 - Safety, PK and Efficacy of PCS12852 on Gastric Emptying Rate in Patients With Moderate to Severe Gastroparesis | Biotech Hunter | Biotech Hunter